Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models

Yi-Qing Qu(Qilu Hospital of Shandong University), Hao Li(Hunan Normal University)
Journal of Experimental & Clinical Cancer Research
June 17, 2014
Cited by 47


Related Papers